<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515592</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1694</org_study_id>
    <nct_id>NCT01515592</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers</brief_title>
  <official_title>A Randomised, Double-blind Within Dose Group, Single Centre, Placebo-controlled, Dose Escalation, Multiple s.c. Dose Study to Assess the Safety and Tolerability of Liraglutide 20 ug/kg and 25 ug/kg in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The aim of this trial is to assess the safety and
      tolerability of 20 µg/kg and 25 µg/kg liraglutide in healthy Japanese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody against liraglutide</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma liraglutide concentration curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, terminal elimination half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour profiles of plasma glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour profiles of serum insulin</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>15 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg</description>
    <arm_group_label>15 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks</description>
    <arm_group_label>20 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks</description>
    <arm_group_label>25 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1</description>
    <arm_group_label>15 mcg/kg</arm_group_label>
    <arm_group_label>20 mcg/kg</arm_group_label>
    <arm_group_label>25 mcg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese subjects

          -  BMI (Body Mass Index) between 18.0-27.0 kg/m^2 inclusive

        Exclusion Criteria:

          -  Any clinical laboratory values deviated from the reference range at the laboratory
             (except for cases within physiological change) or any abnormal ECG (electrocardiogram)
             findings at the screening

          -  Presence of diabetes, cancer or any clinically significant cardiac, respiratory,
             metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological,
             venereal, haematological, neurological, or psychiatric diseases or disorders

          -  Hepatitis B surface antigen, Hepatitis C antibodies or HIV (human immunodeficiency
             virus) antibodies positive

          -  History of diabetes, cancer or any clinically significant cardiac, respiratory,
             metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological,
             venereal, haematological, neurological, or psychiatric diseases or disorders

          -  History of significant allergy or hypersensitivity

          -  Known or suspected allergy to trial product or related products

          -  History of drug or alcohol abuse

          -  The subjects who smoke more than 15 cigarettes, or the equivalent, per day and is
             unwilling to refrain from smoking whenever required for the trial procedure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther. 2008 Jun;46(6):273-9.</citation>
    <PMID>18541123</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

